Asiantuntijamme ovat kirjoittaneet, osallistuneet ja antaneet näkemystä satoihin julkaisuihin.
Kangasniemi M, Karki S, Voutilainen A, Saarnio R, Viinamäki L, Häggman-Laitila A. The value that social workers’ competencies add to health care: An integrative review. Health Soc Care Community 2022;30(2):403-414.
Sipponen T, af Björkesten CG, Hallinen T, Ilus T, Soini E, et al. A nationwide real-world study on dynamic ustekinumab dosing and concomitant medication use among Crohn’s disease patients in Finland. Scand J Gastroenterol 2021.
Karki S, et al. The effects of interventions to prevent substance use among adolescents: A systematic review. Journal of Child & Adolescent Substance Abuse 2012; 21(5), 383–413.
Karki S, et al. Self-reported emotional and behavioral problems in Nepalese adolescents from urban and rural areas. Nurs Health Sci 2015;17(1):90-96.
Karki S, Länsimies H, Laukkanen E, Pirskanen M, Pietilä A-M. Substance use by adolescents in the Western Developmental Region of Nepal. J Subst Use 2016;21:1, 98-106.
Halkoaho A, Pietilä A-M, Ebbesen M, Karki S, Kangasniemi M. Cultural aspects related to informed consent in health research: A systematic review. Nurs Ethics 2016;23(6):698-712.
Kangasniemi M, Hipp K, Häggman-Laitila A, Kallio H, Karki S, et al. Optimoitu sote-ammattilaisten koulutus- ja osaamisuudistus. Valtioneuvoston selvitys- ja tutkimustoiminnan julkaisusarja 39/2018.
Häggman-Laitila A, Salokekkilä P, Karki S. Young People’s Preparedness for Adult Life and Coping After Foster Care: A Systematic Review of Perceptions and Experiences in the Transition Period. Child & Youth Care Forum 2019; 48(12):1-29.
Karki S. Substance use and psychosocial problems among Nepalese adolescents. Doctoral dissertation. Publications of the University of Eastern Finland. Dissertations in Health Sciences, 406. Kuopio: University of Eastern Finland, 2017.
Ronkainen V-P, Ronkainen JJ, Hänninen SL, Leskinen H, Ruas JL, Pereira T, Poellinger L, Vuolteenaho O, Tavi P. Hypoxia inducible factor regulates the cardiac expression and secretion of apelin. FASEB J 2007; 21(8): 1821-30.
Korhonen T, Hänninen SL, Tavi P. Model of excitation-contraction coupling of rat neonatal ventricular myocytes. Biophys J 2009; 96(3):1189-209.
Aydin J, Andersson DC, Hänninen SL, Wredenberg A, Tavi P, Park CB, Larsson N-G, Bruton JD, Westerblad H. Increased mitochondrial Ca2+ and decreased sarcoplasmic reticulum Ca2+ in mitochondrial myopathy. Hum Mol Genet 2009; 18(2): 278-88.
Tavi P, Korhonen T, Hänninen SL, Bruton JD, Lööf S, Simon A, Westerblad H. Myogenic skeletal muscle satellite cells communicate by tunnelling nanotubes. J Cell Physiol 2010; 223(2): 376-83.
Hänninen SL, Ronkainen JJ, Leskinen H, Tavi. Mitochondrial uncoupling downregulates calsequestrin expression and reduces SR Ca2+ stores in cardiomyocytes. Cardiovasc Res 2010; 88(1):75-82.
Ronkainen JJ, Hänninen SL, Korhonen T, Koivumäki JT, Skoumal R, Rautio S, Ronkainen Veli-Pekka, Tavi P. Ca2+-calmodulin-dependent protein kinase II represses cardiac transcription of the L-type calcium channel alpha(1C)-subunit gene (Cacna1c) by DREAM translocation. J Physiol 2011; 598(Pt 11): 2669-86.
Karppinen S, Rapila R, Mäkikallio K, Hänninen SL, Rysä J, Vuolteenaho O, Tavi P. Endothelin-1 signalling controls early embryonic heart rate in vitro and in vivo. Acta Physiol (Oxf) 2014; 210(2): 369-80.
Karppinen S, Rapila R, Naumenko N, Tuomainen T, Koivumäki JT, Hänninen SL, Korhonen T, Tavi P. Ca2+-activated K+ current is essential for maintaining excitability and gene transcription in early embryonic cardiomyocytes. Acta Physiol 2015; 215: 7-9.
Karppinen S, Hänninen SL, Rapila R, Tavi P. Sarcoplasmic reticulum Ca2+ -induced Ca2+ release regulates class IIa HDAC localization in mouse embryonic cardiomyocytes. Physiol Rep. 2018; 6(2):e13522.
Häggman-Laitila A, Salokekkilä P, Karki S. Integrative review of the evaluation of additional support programs for care leavers making the transition to adulthood. J Pediatr Nurs 2020;54:63-77.
Af Björkesten CG, Ilus T, Hallinen T, Soini E, et al. Objectively assessed disease activity and drug persistence during ustekinumab treatment in a nationwide real-world Crohn's disease cohort. Eur J Gastroenterol Hepatol 2020 (online ahead of print).
af Björkesten CG, Ilus T, Hallinen T, Soini E, et al. Real-life dosing patterns and concomitant drug use among ustekinumab-treated patients with Crohn’s disease. Digital Oral Poster (DOP) 26. Journal of Crohn's and Colitis 2020;14 (Issue Supplement 1):S066.
af Björkesten CG, Ilus T, Hallinen T, Soini E, et al. Objectively assessed disease activity during ustekinumab treatment in a nationwide real-life Crohn’s disease cohort. Journal of Crohn's and Colitis 2020;14 (Issue Supplement 1):S434–S435.
Väätäinen S. Diabetesriski, suurentunut paastoglukoosi ja heikentynyt glukoosinsieto ovat yhteydessä heikentyneeseen terveyteen liittyvään elämänlaatuun. Erikoislääkäri 2020;30(2):56-8.
Väätäinen S. Health Utility along the diabetes continuum, examination of utility values in impaired glucose metabolism using pre-scored multi-attribute utility instruments. Doctoral dissertation. Publications of the University of Eastern Finland. Dissertations in Health Sciences, no 555. Kuopio: University of Eastern Finland, 2020.
Kakkostyypin diabeteksen tutkija myöntää: "Terveiden elämäntapojen noudattaminen on haaste itsellenikin." Mediuutiset 2020;(18):13. Medipersoona: Väätäinen S.
Psoriaasi ja nivelpsoriaasi. Käypä hoito -suositus. Suomalaisen Lääkäriseuran Duodecimin ja Suomen Ihotautilääkäriyhdistyksen asettama työryhmä. Helsinki: Suomalainen Lääkäriseura Duodecim, 2020 (viitattu 4.8.2020). Asiantuntija: Soini E.
Väätäinen S, Soini E, et al. Economic Value of Adjunctive Brivaracetam Treatment Strategy for Focal Onset Seizures in Finland. Adv Ther 2020; 37: 477-500.
Heiskanen J, Hartikainen J, Martikainen J, et al. Purchases of medical therapy recommended for coronary artery disease before and after elective revascularisation. Eur J Clin Pharmacol. 2020;76(1):81-88.
Väätäinen S, Soini E, et al. Alemtuzumab is a budget-saving alternative to fingolimod and natalizumab in the treatment of highly active relapsing-remitting multiple sclerosis. Dosis 2020;36(1):36-59.
Mankinen P, Lundström T, Soini E, et al. Cost Assessment Modelling of Treatments for Highly Active Relapsing Multiple Sclerosis. Adv Ther 2020;37 (2): 800-18.